A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
Status:
Completed
Trial end date:
1992-01-01
Target enrollment:
Participant gender:
Summary
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with
advanced HIV disease and T4 cell count < 200 cells/mm3. To establish the range of pentamidine
(PEN) deposition in AIDS patients participating in ACTG 021 and ACTG 081. To identify factors
(breathing pattern, pulmonary function) that may be important in affecting the actual dose
delivered to a given patient.
The specific system that is used to deliver PEN to the lungs may determine whether a
therapeutically effective dose is attained in the lungs. Therefore, this study will establish
the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021
and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II
nebulizer.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)